CHAI TLD Clinical Action Memo
- hivtoolkit
- Jul 24, 2018
- 1 min read

This memo lays out information for programs considering introducing improved first-line products and implementation guidance for transitioning to dolutegravir (DTG) as the preferred first-line regimen, in line with WHO treatment guidelines.
Comments